ArticleFrontiers in oncology2026

Pembrolizumab for MSI-high/TMB-high bone and soft tissue sarcomas: a retrospective single-institution study.

Tomonori Kawasaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.